The Categorization of Nitrosamines by the U.S. FDA

The issue of nitrosamine impurities has become one of the most significant regulatory concerns in the pharmaceutical industry since 2018. Following the detection of nitrosamine contamination in several widely used medicines, the U.S. Food and Drug Administration (FDA) issued comprehensive guidance to assist manufacturers in identifying, assessing, and controlling these potentially carcinogenic impurities.

A cornerstone of this regulatory framework is the categorization of nitrosamines, which divides them into two primary groups based on structure, origin, and toxicological evaluation approach.

1️⃣ Small-Molecule Nitrosamines

Small-molecule nitrosamines are low molecular weight compounds that are not structurally related to the active pharmaceutical ingredient (API). They are typically formed when amines react with nitrosating agents (e.g., nitrites) during manufacturing or storage.

Common Examples:

• NDMA (N-nitrosodimethylamine)
• NDEA (N-nitrosodiethylamine)

Typical Formation Conditions

• Presence of secondary or tertiary amines
• Nitrites or nitrosating agents
• Acidic environment
• Heat or prolonged storage

Regulatory Advantage

Many small-molecule nitrosamines have existing carcinogenicity data, allowing FDA to establish substance-specific acceptable intake (AI) limits.

2️⃣ Nitrosamine Drug Substance-Related Impurities (NDSRIs)

Nitrosamine Drug Substance-Related Impurities (NDSRIs) are formed when the API itself or an API fragment undergoes nitrosation. These impurities are structurally related to the drug substance.

Key Characteristics

• Structurally derived from the API
• Often product-specific
• Frequently lack compound-specific toxicology data
• Require predictive modeling approaches

Because they are unique and structurally complex, NDSRIs pose greater regulatory and scientific challenges compared to small-molecule nitrosamines.

Key Differences Between Small-Molecule Nitrosamines and NDSRIs

The FDA’s classification is not merely academic—it determines the risk assessment pathway, toxicological evaluation strategy, and regulatory control expectations.

In summary, small-molecule nitrosamines are typically well-characterized contaminants, while NDSRIs are structurally unique impurities requiring predictive toxicology tools and advanced risk modeling approaches.

Acceptable Intake (AI) Determination

Consistent with ICH M7(R2) principles, FDA defines acceptable intake limits based on a theoretical lifetime cancer risk of 1 additional case in 100,000 individuals.

For NDSRIs, FDA’s RAIL Guidance outlines three approaches:

1. Substance-specific carcinogenicity data
2. Surrogate-based evaluation
3. Predicted carcinogenic potency categorization

If none apply, FDA recommends a conservative default limit of 26.5 ng/day.

Risk Assessment and Control Strategy

Manufacturers are expected to:

• Conduct comprehensive risk assessments
• Perform validated analytical testing (e.g., LC-MS/MS)
• Establish specifications if levels exceed 10% of AI
• Optimize processes to prevent formation
• Audit suppliers and raw materials
• Assess packaging and storage conditions

Frequently Asked Questions (FAQs)

1. Why did the FDA categorize nitrosamines into two types?

The categorization helps determine the appropriate toxicological evaluation and regulatory control strategy, as small-molecule nitrosamines and NDSRIs differ significantly in structure and risk assessment approach.

2. Are all nitrosamines carcinogenic?

Not all nitrosamines have equal carcinogenic potency. Some are classified as probable human carcinogens, while others require predictive modeling due to limited data.

3. What is the default acceptable intake limit when no data exists?

If no substance-specific or surrogate data is available, FDA generally recommends a conservative default AI of 26.5 ng/day.

4. Why are NDSRIs more challenging to regulate?

Because they are structurally unique and often lack toxicological data, regulators must rely on predictive carcinogenic potency categorization models.

5. What triggers the need for a specification limit?

If analytical testing shows a nitrosamine impurity exceeds 10% of its acceptable intake limit, a formal specification should be implemented.

6. Can multiple nitrosamines be present in a single product?

Yes. In such cases, total exposure should not exceed the acceptable intake of the most potent nitrosamine unless justified otherwise.

7. How can manufacturers prevent nitrosamine formation?

By avoiding secondary/tertiary amines, replacing nitrites, optimizing process conditions, auditing suppliers, and controlling storage/packaging.

8. Do NDSRIs apply only to APIs?

NDSRIs originate from APIs or API fragments but may be detected in both drug substances and finished drug products.

9. Are acceptable intake limits permanent?

No. AI limits may be revised as new toxicological data becomes available.

10. Does FDA require immediate recalls for any nitrosamine detection?

Not necessarily. FDA evaluates risk based on exposure level, duration, and AI limits before determining regulatory action.

Conclusion

The FDA’s structured categorization of nitrosamines into Small-Molecule Nitrosamines and NDSRIs provides a scientifically robust framework for impurity assessment and control. This distinction ensures appropriate toxicological evaluation, regulatory clarity, and ultimately, patient safety.